DALLAS, Feb. 24, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/SOMX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The Company is focused on the development of Silenor. SOMX completed its new drug application (NDA) for Silenor and submitted it to the U.S. Food and Drug Administration (FDA) on January 31, 2008.
Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX
In the report, the analyst notes:
"For the third quarter of 2009, net loss applicable to common stockholders was $1.8 million, or 8 cents per share, compared with $10.3 million, or 56 cents per share, for the third quarter of 2008. As a development stage pharmaceutical company, SOMX had no revenues during the third quarter of 2009.
"SOMX in late January provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. SOMX held a meeting with senior leadership at the U.S. Food and Drug Administration (FDA) on January 20, 2010, to discuss the issues raised by the FDA in the Complete Response Letter SOMX received in December 2009 relating to the Silenor NDA. The only remaining efficacy issue was related to the robustness of sustained subjective sleep maintenance efficacy in non-elderly adults with primary insomnia."
To read the entire report visit: http://www.investorsoup.com/lp/SOMX
See what investors say about SOMX at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.